A pharmacy that puts an unscreened employee in a room with controlled substances is not just making a personnel mistake. Under 21 C.F.R. § 1301.76(a), a DEA registrant shall not employ any agent or employee with access to controlled substances who has been convicted of a controlled-substance felony, or who has ever had a DEA registration denied, revoked, or surrendered for cause. That is a flat prohibition, not a factor to weigh. A pharmacist-in-charge who never asks the question, and later discovers the answer during a DEA inspection, has already built a security-control violation into the pharmacy's own registrant file.
What 21 CFR 1301.76 Requires
Section 1301.76 governs security controls for practitioners, the DEA registrant category that includes retail pharmacies. The regulation defines for cause as a surrender made in lieu of, or as a consequence of, any federal or state administrative, civil, or criminal action arising from an investigation into the individual's handling of controlled substances. A prior felony drug conviction or a for-cause DEA history is disqualifying on its face. There is no discretion built into the rule for a pharmacist-in-charge who likes the candidate or is short-staffed.
The DEA's Employee Screening Questions
A separate provision, 21 C.F.R. § 1301.90, was written for non-practitioner registrants such as manufacturers and distributors, but DEA's own screening questions from that section are the standard the industry has adopted for anyone hiring into a controlled-substance environment, pharmacies included. DEA calls the underlying rationale a business necessity essential to controlled substances security. The recommended questions ask whether the applicant has been convicted of a felony in the past five years, or a misdemeanor in the past two years, and whether the applicant has knowingly used narcotics, amphetamines, or barbiturates without a prescription in the past three years. A written authorization allowing the pharmacy to check with courts and law enforcement for pending charges or convictions accompanies the screening.
A pharmacy that never asks the screening question cannot later claim it did not know the answer.
The Duty to Inquire Does Not End at Hiring
Under 21 C.F.R. § 1301.91, an employee who learns of drug diversion by a coworker has an obligation to report it to a responsible security official, and the employer must protect the confidentiality of that report. A failure to report is a factor DEA weighs in deciding whether that employee should keep working in a drug security area. The duty to inquire, in other words, is not a one-time intake form. It runs through the length of employment, and a pharmacist-in-charge who has no protocol for staff to report suspected diversion is exposed on the same theory as one who skipped the hiring screen.
What a Screening Gap Costs at Inspection
Employee screening is one of several security-control obligations DEA reviews during a pharmacy inspection, alongside suspicious order monitoring and inventory reconciliation. An investigator who finds an employee with a disqualifying record on staff, or no screening file at all, can cite the gap as a security-control violation in the registrant's own file, which becomes evidence in a broader review of the pharmacy's controlled-substance operations.
In the more serious cases, a screening failure tied to an actual diversion incident becomes part of the record DEA cites in an order to show cause proceeding, and where the agency finds an imminent danger to public health or safety, it can pair that order with an immediate suspension order that halts the registration before a hearing. Health Law Alliance's guide to responding to a DEA order to show cause walks through that process in detail.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a DEA inspection notice, subpoena, or order to show cause tied to employee screening or diversion findings. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to DEA requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk, particularly where a screening gap is cited alongside other recordkeeping findings.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies nationwide in DEA inspections, employee screening compliance reviews, and order to show cause proceedings, drawing on the firm's experience with 2,000+ audits overseen on behalf of pharmacy clients. Pharmacies that have questions about an employee screening protocol, or that have received a DEA inspection notice citing a screening or diversion-reporting gap, may contact Health Law Alliance's DEA defense team for a free, confidential consultation.
